Aquestive Therapeutics (AQST) Accumulated Depreciation (2017 - 2021)

Aquestive Therapeutics' Accumulated Depreciation history runs 5 years deep, the most recent figure standing at $37.8 million for Q1 2021.

• On a quarterly basis, Accumulated Depreciation fell 2.39% year-over-year to $37.8 million in Q1 2021; TTM through Mar 2021 was $37.8 million, a 2.39% decrease from a year earlier, with the FY2020 full-year figure at $40.9 million, up 7.45% from the prior year.
• Accumulated Depreciation eased to $37.8 million in Q1 2021 per AQST's latest filing, from $40.9 million in the prior quarter.
• Across five years, Accumulated Depreciation topped out at $40.9 million in Q4 2020 and bottomed at $32.0 million in Q4 2017.
• The 5-year median for Accumulated Depreciation is $37.3 million (2019), against an average of $37.0 million.
• Across the five-year window, Accumulated Depreciation rose 9.95% in 2018 and fell 2.39% in 2021, its largest moves.
• Year by year, Accumulated Depreciation stood at $32.0 million in 2017, then increased by 9.95% to $35.2 million in 2018, then increased by 8.11% to $38.0 million in 2019, then increased by 7.45% to $40.9 million in 2020, then decreased by 7.45% to $37.8 million in 2021.
• Per Business Quant, the three latest AQST Accumulated Depreciation figures stand at $37.8 million (Q1 2021), $40.9 million (Q4 2020), and $40.2 million (Q3 2020).